Arsenic Trioxide

3 trials 1 recruiting LOncology Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

3 Sponsors

9 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 1 Phase II: 1 Phase I (Other): 1

Sponsors using this IMP

Associazione Italiana Ematologia Oncologia Pediatrica 1 Groupe Francophone Des Myelodysplasies 1 Quetzal Therapeutics LLC 1

All trials

3 total

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Pending

2025-524810-28-00 Phase III 6 countries Quetzal Therapeutics LLC
Oral arsenic (ATO) in low-risk myelodysplastic syndromes (MDS) failing Erythropoiesis Stimulating Agents and Luspatercept Recruiting

2024-515311-22-00 Phase I (Other) 1 country Groupe Francophone Des Myelodysplasies
ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended

2024-518669-83-00 Phase II 5 countries Associazione Italiana Ematologia Oncologia Pediatrica

Showing 1–3 of 3 trials

← All drugs A–Z